Optimal doses of H1 antihistamines do not increase susceptibility to febrile convulsions in children

Publication date: Available online 18 May 2018
Source:Pediatric Neurology
Author(s): Kosuke Yonemoto, Kazuo Okanari, Hiroshi Koga
BackgroundThe purpose of this study was to elucidate whether H1 antihistamine administration increases susceptibility to febrile convulsions in children.MethodsA single-center, retrospective observational study was conducted in Japan. The study included 380 children with febrile convulsions between the ages of 6 months and 5 years transported via ambulance from 2011 through 2016. They were divided into the pre-seizure H1 antagonist "use group" and the "non-use group." The former consisted of children who took H1 antagonists within 24 hours prior to the seizure onset. The primary outcome (seizure duration) and the secondary outcome (interval from fever to seizure onset) were compared between the two groups.ResultsOf the 380 study patients, 70 (18%) were identified as the use group. None of the patients were taking excessive doses of H1 antagonists. The prevalence of seizures lasting 15 minutes or longer was not different between the use group and the non-use group (11% vs. 8%, prevalence ratio 1.47 [95% confidence interval (CI), 0.63 – 3.42], P=0.37). The prevalence of fever to seizure onset <6 hours was significantly lower in the use group (26% vs. 52%, prevalence ratio 0.33 [95%CI 0.19 – 0.60], P<0.001). Similar results were obtained when analyses were conducted separately by different generations (first and second) of H1 antagonists.ConclusionsProlonged seizure duration and shortened interval from fever to seizure were not observed in children who received H1 antagonists. This study provides evidence that H1 antagonists at optimal doses could be safely used in febrile children with allergic symptoms.



https://ift.tt/2IztK1F